Dual Effect of Interferon (IFNγ)-Induced Nitric Oxide on Tumorigenesis and Intracellular Bacteria

Vitamins and Hormones

Volumn 96, Issue , 2014, Pages 299-321

  Zea, Arnold H ^a   Aiyar, Ashok ^a   Tate, David ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arginase; Citrulline; Inducible nitric oxide synthase; Interferon gamma; L Arginine; Nitric oxide; Polyamines; Renal cell carcinoma; Tuberculosis

Indexed keywords

GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ANIMAL; BACTERIA; CARCINOGENESIS; DRUG EFFECTS; METABOLISM;

ANIMALS; BACTERIA; CARCINOGENESIS; INTERFERON-GAMMA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II;

EID: 84906835015     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800254-4.00012-X     Document Type: Chapter

References (91)

1. Agnello D., Lankford C.S., Bream J., Morinobu A., Gadina M., O'Shea J.J., et al. Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights. Journal of Clinical Immunology 2003, 23:147-161.
2. Ahlin A., Larfars G., Elinder G., Palmblad J., Gyllenhammar H. Gamma interferon treatment of patients with chronic granulomatous disease is associated with augmented production of nitric oxide by polymorphonuclear neutrophils. Clinical and Diagnostic Laboratory Immunology 1999, 6:420-424.
3. Ambs S., Ogunfusika M.O., Merriam W.G., Bennett W.P., Billiar T.R., Harris C.C. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:8823-8828.
4. Angiolillo A.L., Sgadari C., Taub D.D., Liao F., Farber J.M., Maheshwari S., et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. The Journal of Experimental Medicine 1995, 182:155-162.
5. Ash D.E. The structure and function of arginases. The Journal of Nutrition 2004, 134(10 suppl):2760S-2764S.
6. Au-Yeung N., Mandhana R., Horvath C.M. Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. JAK-STAT 2013, 2:e23931.
7. Bernabei P., Allione A., Rigamonti L., Bosticardo M., Losana G., Borghi I., et al. Regulation of interferon-gamma receptor (INF-gammaR) chains: A peculiar way to rule the life and death of human lymphocytes. European Cytokine Network 2001, 12:6-14.
8. Bogdan C. Nitric oxide and the immune response. Nature Immunology 2001, 2:907-916.
9. Bronte V., Zanovello P. Regulation of immune responses by l-arginine metabolism. Nature Reviews Immunology 2005, 5:641-654.
10. Brown T.J., Lioubin M.N., Marquardt H. Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. Journal of Immunology 1987, 139:2977-2983.
11. Brunelli L., Yermilov V., Beckman J.S. Modulation of catalase peroxidatic and catalatic activity by nitric oxide. Free Radical Biology and Medicine 2001, 30:709-714.
12. Bryk J., Ochoa J.B., Correia M.I., Munera-Seeley V., Popovic P.J. Effect of citrulline and glutamine on nitric oxide production in RAW 264.7 cells in an arginine-depleted environment. Journal of Parenteral and Enteral Nutrition 2008, 32:377-383.
13. Buga G.M., Wei L.H., Bauer P.M., Fukuto J.M., Ignarro L.J. NG-hydroxy-l-arginine and nitric oxide inhibit Caco-2 tumor cell proliferation by distinct mechanisms. The American Journal of Physiology 1998, 275:R1256-R1264.
14. Choi B.S., Martinez-Falero I.C., Corset C., Munder M., Modolell M., Muller I., et al. Differential impact of l-arginine deprivation on the activation and effector functions of T cells and macrophages. Journal of Leukocyte Biology 2009, 85:268-277.
15. Condos R., Rom W.N., Schluger N.W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997, 349:1513-1515.
16. Dachs G.U., Tozer G.M. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation. European Journal of Cancer 2000, 36:1649-1660.
17. Dutcher J.P. Interleukin-2 based therapy for kidney cancer. Cancer Treatment and Research 2003, 116:155-172.
18. El Kasmi K.C., Qualls J.E., Pesce J.T., Smith A.M., Thompson R.W., Henao-Tamayo M., et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nature Immunology 2008, 9:1399-1406.
19. Ellerhorst J.A., Kilbourn R.G., Amato R.J., Zukiwski A.A., Jones E., Logothetis C.J. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. The Journal of Urology 1994, 152:841-845.
20. Ernstoff M.S., Nair S., Bahnson R.R., Miketic L.M., Banner B., Gooding W., et al. A phase IA trial of sequential administration recombinant DNA-produced interferons: Combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 1990, 8:1637-1649.
21. Finke J.H., Rini B., Ireland J., Rayman P., Richmond A., Golshayan A., et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clinical Cancer Research 2008, 14:6674-6682.
22. Forstermann U., Boissel J.P., Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). The FASEB Journal 1998, 12:773-790.
23. Garcia-Tunon I., Ricote M., Ruiz A.A., Fraile B., Paniagua R., Royuela M. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 2007, 7:158.
24. Gotoh T., Mori M. Arginase II downregulates nitric oxide (NO) production and prevents NO-mediated apoptosis in murine macrophage-derived RAW 264.7 cells. The Journal of Cell Biology 1999, 144:427-434.
25. Haas G.P., Hillman G.G. Update on the role of immunotherapy in the management of kidney cancer. Cancer Control 1996, 3:536-541.
26. Harris J., De Haro S.A., Master S.S., Keane J., Roberts E.A., Delgado M., et al. T helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium tuberculosis. Immunity 2007, 27:505-517.
27. Hatano E., Bennett B.L., Manning A.M., Qian T., Lemasters J.J., Brenner D.A. NF-kappaB stimulates inducible nitric oxide synthase to protect mouse hepatocytes from TNF-alpha- and Fas-mediated apoptosis. Gastroenterology 2001, 120:1251-1262.
28. Heinrich T.A., Tedesco A.C., Fukuto J.M., da Silva R.S. Production of reactive oxygen and nitrogen species by light irradiation of a nitrosyl phthalocyanine ruthenium complex as a strategy for cancer treatment. Dalton Transactions 2014, 43:4021-4025.
29. Heneka M.T., Feinstein D.L. Expression and function of inducible nitric oxide synthase in neurons. Journal of Neuroimmunology 2001, 114:8-18.
30. Herbst S., Schaible U.E., Schneider B.E. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS One 2011, 6:e19105.
31. Hillman G.G., Younes E., Visscher D., Hamzavi F., Kim S., Lam J.S., et al. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: Mechanism of action and potential for combination with interleukin 4. Clinical Cancer Research 1997, 3:1799-1806.
32. Hinz B., Brune K., Pahl A. Nitric oxide inhibits inducible nitric oxide synthase mRNA expression in RAW 264.7 macrophages. Biochemical and Biophysical Research Communications 2000, 271:353-357.
33. Hu D.E., Dyke S.O., Moore A.M., Thomsen L.L., Brindle K.M. Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. Cancer Research 2004, 64:152-161.
34. Huie R.E., Padmaja S. The reaction of no with superoxide. Free Radical Research Communications 1993, 18:195-199.
35. Hussain S.P., Trivers G.E., Hofseth L.J., He P., Shaikh I., Mechanic L.E., et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Research 2004, 64:6849-6853.
36. Ignarro L.J. The unique role of nitric oxide as a signaling molecule in the cardiovascular system. Italian Heart Journal 2000, 1(Suppl. 3):S28-S29.
37. Ischiropoulos H., Beckman J.S. Oxidative stress and nitration in neurodegeneration: Cause, effect, or association?. The Journal of Clinical Investigation 2003, 111:163-169.
38. Joshi M.S., Ferguson T.B., Han T.H., Hyduke D.R., Liao J.C., Rassaf T., et al. Nitric oxide is consumed, rather than conserved, by reaction with oxyhemoglobin under physiological conditions. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:10341-10346.
39. Jost M.M., Ninci E., Meder B., Kempf C., Van R.N., Hua J., et al. Divergent effects of GM-CSF and TGFbeta1 on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix metalloproteinase-12: A potential role during arteriogenesis. The FASEB Journal 2003, 17:2281-2283.
40. Kim I.Y., Stadtman T.C. Inhibition of NF-kappaB DNA binding and nitric oxide induction in human T cells and lung adenocarcinoma cells by selenite treatment. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:12904-12907.
41. Kleinert H., Schwarz P.M., Forstermann U. Regulation of the expression of inducible nitric oxide synthase. Biological Chemistry 2003, 384:1343-1364.
42. Klimp A.H., de Vries E.G., Scherphof G.L., Daemen T. A potential role of macrophage activation in the treatment of cancer. Critical Reviews in Oncology/Hematology 2002, 44:143-161.
43. Kroncke K.D., Fehsel K., Suschek C., Kolb-Bachofen V. Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. International Immunopharmacology 2001, 1:1407-1420.
44. Kropf P., Fuentes J.M., Fahnrich E., Arpa L., Herath S., Weber V., et al. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. The FASEB Journal 2005, 19:1000-1002.
45. Lala P.K., Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. The Lancet Oncology 2001, 2:149-156.
46. Larkin J., Ahmed C.M., Wilson T.D., Johnson H.M. Regulation of interferon gamma signaling by suppressors of cytokine signaling and regulatory T cells. Frontiers in Immunology 2013, 4:469.
47. Li H., Meininger C.J., Hawker J.R., Haynes T.E., Kepka-Lenhart D., Mistry S.K., et al. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. American Journal of Physiology, Endocrinology and Metabolism 2001, 280:E75-E82.
48. Lollini P.L., Bosco M.C., Cavallo F., De G.C., Giovarelli M., Landuzzi L., et al. Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. International Journal of Cancer 1993, 55:320-329.
49. Luiking Y.C., Hallemeesch M.M., van de Poll M.C., Dejong C.H., de Jonge W.J., Lamers W.H., et al. Reduced citrulline availability by OTC deficiency in mice is related to reduced nitric oxide production. American Journal of Physiology, Endocrinology and Metabolism 2008, 295:E1315-E1322.
50. MacMicking J., Xie Q.W., Nathan C. Nitric oxide and macrophage function. Annual Review of Immunology 1997, 15:323-350.
51. Miller C.H., Maher S.G., Young H.A. Clinical use of interferon-gamma. The Annals of the New York Academy of Sciences 2009, 1182:69-79.
52. Mishra B.B., Rathinam V.A., Martens G.W., Martinot A.J., Kornfeld H., Fitzgerald K.A., et al. Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta. Nature Immunology 2013, 14:52-60.
53. Mocellin S., Bronte V., Nitti D. Nitric oxide, a double edged sword in cancer biology: Searching for therapeutic opportunities. Medicinal Research Reviews 2007, 27:317-352.
54. Mocellin S., Provenzano M., Rossi C.R., Pilati P., Scalerta R., Lise M., et al. Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity. Clinical Cancer Research 2004, 10:6879-6886.
55. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. Journal of Clinical Oncology 2002, 20:289-296.
56. Munder M., Eichmann K., Modolell M. Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: Competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. The Journal of Immunology 1998, 160:5347-5354.
57. Munder M., Schneider H., Luckner C., Giese T., Langhans C.D., Fuentes J.M., et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006, 108:1627-1634.
58. Nathan C. Inducible nitric oxide synthase in the tuberculous human lung. American Journal of Respiratory and Critical Care Medicine 2002, 166:130-131.
59. Nathan C., Shiloh M.U. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:8841-8848.
60. O'Brien L., Carmichael J., Lowrie D.B., Andrew P.W. Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infection and Immunity 1994, 62:5187-5190.
61. O'Shea J.J., Gadina M., Kanno Y. Cytokine signaling: Birth of a pathway. The Journal of Immunology 2011, 187:5475-5478.
62. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiological Reviews 2007, 87:315-424.
63. Park S.K., Cho S., Lee I.H., Jeon D.S., Hong S.H., Smego R.A., et al. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. International Journal of Infectious Diseases 2007, 11:434-440.
64. Peranzoni E., Marigo I., Dolcetti L., Ugel S., Sonda N., Taschin E., et al. Role of arginine metabolism in immunity and immunopathology. Immunobiology 2007, 212:795-812.
65. Perske C., Lahat N., Sheffy L.S., Bitterman H., Hemmerlein B., Rahat M.A. Loss of inducible nitric oxide synthase expression in the mouse renal cell carcinoma cell line RENCA is mediated by microRNA miR-146a. The American Journal of Pathology 2010, 177:2046-2054.
66. Pestka S., Krause C.D., Walter M.R. Interferons, interferon-like cytokines, and their receptors. Immunological Reviews 2004, 202:8-32.
67. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives. Immunological Reviews 2008, 222:180-191.
68. Rosenberg S.A., Lotze M.T., Yang J.C., Linehan W.M., Seipp C., Calabro S., et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. Journal of Clinical Oncology 1989, 7:1863-1874.
69. Schairer D.O., Chouake J.S., Nosanchuk J.D., Friedman A.J. The potential of nitric oxide releasing therapies as antimicrobial agents. Virulence 2012, 3:271-279.
70. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: An overview of signals, mechanisms and functions. Journal of Leukocyte Biology 2004, 75:163-189.
71. Serafini P., Carbley R., Noonan K.A., Tan G., Bronte V., Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Research 2004, 64:6337-6343.
72. Shah V., Lyford G., Gores G., Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology 2004, 126:903-913.
73. Shang D., Qi Q.H., Wang B.Z., Chen H.L., Bi W., Guan F.L. Role of polymorphonuclear neutrophil apoptosis and expression of Fas and caspase-3 in the systemic inflammatory response syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2007, 19:11-13.
74. Sharma S.K., Banga A. Diagnostic utility of pleural fluid IFN-gamma in tuberculosis pleural effusion. Journal of Interferon and Cytokine Research 2004, 24:213-217.
75. Shinoda J., McLaughlin K.E., Bell H.S., Swaroop G.R., Yamaguchi S., Holmes M.C., et al. Molecular mechanisms underlying dexamethasone inhibition of iNOS expression and activity in C6 glioma cells. Glia 2003, 42:68-76.
76. Spencer W.F., Linehan W.M., Walther M.M., Haas G.P., Lotze M.T., Topalian S.L., et al. Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: A pilot study. The Journal of Urology 1992, 147:24-30.
77. Tate D.J., Vonderhaar D.J., Caldas Y.A., Metoyer T., Patterson J.R., Aviles D.H., et al. Effect of arginase II on l-arginine depletion and cell growth in murine cell lines of renal cell carcinoma. Journal of Hematology and Oncology 2008, 1:14.
78. Trinchieri G. Type I interferon: Friend or foe?. The Journal of Experimental Medicine 2010, 207:2053-2063.
79. Viola A., Bronte V. Metabolic mechanisms of cancer-induced inhibition of immune responses. Seminars in Cancer Biology 2007, 17:309-316.
80. Willenborg D.O., Staykova M., Fordham S., O'Brien N., Linares D. The contribution of nitric oxide and interferon gamma to the regulation of the neuro-inflammation in experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 2007, 191:16-25.
81. Windbichler G.H., Hausmaninger H., Stummvoll W., Graf A.H., Kainz C., Lahodny J., et al. Interferon-gamma in the first-line therapy of ovarian cancer: A randomized phase III trial. British Journal of Cancer 2000, 82:1138-1144.
82. Wink D.A., Hines H.B., Cheng R.Y., Switzer C.H., Flores-Santana W., Vitek M.P., et al. Nitric oxide and redox mechanisms in the immune response. Journal of Leukocyte Biology 2011, 89:873-891.
83. Wink D.A., Kasprzak K.S., Maragos C.M., Elespuru R.K., Misra M., Dunams T.M., et al. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991, 254:1001-1003.
84. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998, 19:711-721.
85. Wu G., Bazer F.W., Davis T.A., Kim S.W., Li P., Marc R.J., et al. Arginine metabolism and nutrition in growth, health and disease. Amino Acids 2009, 37:153-168.
86. Wu G.Y., Brosnan J.T. Macrophages can convert citrulline into arginine. Biochemical Journal 1992, 281(Pt 1):45-48.
87. Xie Q.W., Cho H.J., Calaycay J., Mumford R.A., Swiderek K.M., Lee T.D., et al. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science 1992, 256:225-228.
88. Xu W., Liu L.Z., Loizidou M., Ahmed M., Charles I.G. The role of nitric oxide in cancer. Cell Research 2002, 12:311-320.
89. Zabaleta J., McGee D.J., Zea A.H., Hernandez C.P., Rodriguez P.C., Sierra R.A., et al. Helicobacter pylori arginase inhibits T cell proliferation and reduces the expression of the TCR zeta-chain (CD3zeta). The Journal of Immunology 2004, 173:586-593.
90. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Research 2005, 65:3044-3048.
91. Zea A.H., Rodriguez P.C., Culotta K.S., Hernandez C.P., DeSalvo J., Ochoa J.B., et al. l-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes. Cellular Immunology 2004, 232:21-31.